Virios Therapeutics to Report Fourth Quarter & Full Year 2020 Financial Results & Provide Corporate Update on Thursday, March...
March 11 2021 - 7:05AM
Business Wire
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage
biotechnology company focused on advancing novel antiviral
therapies to treat diseases associated with virally triggered or
maintained immune responses, announced today that its fourth
quarter and full year 2020 financial results will be reported on
Thursday, March 18, 2021 before the open of the financial markets.
Management will also host a webcast and conference call on March
18, 2021 at 8:30 a.m. ET to discuss the results and provide a
corporate update.
The live and archived webcast of the call may be accessed on the
Virios Therapeutics website under the Investors section: Events and
Presentations. The live call can also be accessed by dialing (877)
407-8133 (domestic) or (201) 689-8040 (international) and asking to
be connected to the "Virios Therapeutics Conference Call".
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage
biotechnology company focused on advancing novel, dual mechanism
antiviral therapies to treat conditions associated with virally
triggered or maintained immune responses, such as fibromyalgia
(“FM”). Immune responses related to the activation of tissue
resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a
potential root cause triggering and/or sustaining chronic illnesses
such as FM, irritable bowel disease (“IBS”), chronic fatigue
syndrome and other functional somatic syndromes, all of which are
characterized by waxing and waning symptoms with no obvious
etiology. Our lead development candidate (“IMC-1”) is a novel,
proprietary, fixed dose combination of famciclovir and celecoxib
designed to synergistically suppress HSV-1 replication, with the
end goal of reducing virally promoted disease symptoms.
Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome
measures was previously demonstrated in a Phase 2 clinical trial.
These trial results are suggestive that IMC-1 may represent a new
and novel treatment for fibromyalgia. IMC-1 has been granted fast
track designation by the FDA and is currently being tested in a
multi-center, randomized, double-blind, placebo-controlled Phase 2B
trial designed to set the stage for registrational studies. The
company is led by an executive team highly experienced in the
successful development and commercialization of novel therapies.
For more information, please visit www.virios.com/.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Virios Therapeutics’ current expectations
and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict. Further, certain forward-looking
statements are based on assumptions as to future events that may
not prove to be accurate. These and other risks and uncertainties
are described more fully in the section titled “Risk Factors” in
the final prospectus related to our initial public offering filed
with the Securities and Exchange Commission on December 18, 2020.
Forward-looking statements contained in this announcement are made
as of this date, and Virios Therapeutics, Inc. undertakes no duty
to update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210311005257/en/
Jenny Kobin IR@Virios.com
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Apr 2023 to Apr 2024